Read by QxMD icon Read

Carl June

Courtney B Rubin, Rosalie Elenitsas, Laura Taylor, Simon F Lacey, Irina Kulikovskaya, Minnal Gupta, Jan J Melenhorst, Alison Loren, Noelle Frey, Carl H June, David Porter, Misha Rosenbach
No abstract text is available yet for this article.
November 2016: Journal of the American Academy of Dermatology
Pablo S Corona, Frank Erimeiku, Maria Mercedes Reverté-Vinaixa, Francisco Soldado, Carles Amat, Lluis Carrera
INTRODUCTION: Necrotising fasciitis (NF) is potentially life-threatening soft-tissue infection. Early diagnosis and aggressive surgical debridement are critical to decrease mortality and morbidity. The impacts of new management technologies such as hydro-bisturi-assisted debridement (HAD) and negative pressure wound therapy (NPWT) are not yet clear with respect to treatment of NF. The objective of this study was to describe laboratory (including LRINEC score), clinical and microbiological factors, treatment methods and outcomes related to managing necrotising fasciitis, focusing on the implementation of new treatment methods in our centre...
September 2016: Injury
Michael M Lederman, Paula M Cannon, Judith S Currier, Carl H June, Hans Peter Kiem, Daniel R Kuritzkes, Sharon R Lewin, David M Margolis, Joseph M McCune, John W Mellors, Timothy W Schacker, Rafick P Sekaly, Pablo Tebas, Bruce D Walker, Daniel C Douek
With the advent and stunning success of combination antiretroviral therapy (ART) to prolong and improve quality of life for persons with HIV infection, HIV research has been afforded the opportunity to pivot towards studies aimed at finding "a cure." The mere idea that cure of HIV might be possible has energized researchers and the community towards achieving this goal. Funding agencies, both governmental and private, have targeted HIV cure as a high priority; many in the field have responded to these initiatives and the cure research agenda is robust...
2016: Pathogens & Immunity
Julie C Fitzgerald, Scott L Weiss, Shannon L Maude, David M Barrett, Simon F Lacey, J Joseph Melenhorst, Pamela Shaw, Robert A Berg, Carl H June, David L Porter, Noelle V Frey, Stephan A Grupp, David T Teachey
OBJECTIVE: Initial success with chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through multicenter trials. Cytokine release syndrome, the most severe toxicity, presents a novel critical illness syndrome with limited data regarding diagnosis, prognosis, and therapy. We sought to characterize the timing, severity, and intensive care management of cytokine release syndrome after chimeric antigen receptor-modified T cell therapy...
September 14, 2016: Critical Care Medicine
Sarah Brooks, Noelle Frey, David Porter, Carl June, Simon Lacey, Adam Bagg
No abstract text is available yet for this article.
September 9, 2016: British Journal of Haematology
Joseph R Pierce, Kathleen N Beasley, Amanda J Centi, Dennis E Scofield, Charles H Negus, Rachel K Evans, Carl M Maresh, William J Kraemer, Bradley C Nindl
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
Jason David Allen, Mary N Woessner, Mitch VanBruggen, Thomas Stabler, Johanna L Johnson, Carl Pieper, William E Kraus
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
Cassandra Smith, Mary N Woessner, Mitch VanBruggen, Thomas Stabler, Johanna L Johnson, Carl Pieper, William E Kraus, Jason D Allen
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
Marco Ruella, David M Barrett, Saad S Kenderian, Olga Shestova, Ted J Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F Lacey, Jan J Melenhorst, Jennifer J D Morrissette, David A Christian, Christopher A Hunter, Michael Kalos, David L Porter, Carl H June, Stephan A Grupp, Saar Gill
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients. Developing approaches to preventing and treating antigen-loss escapes would therefore represent a vertical advance in the field. Here, we found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration...
October 3, 2016: Journal of Clinical Investigation
Andrew D Fesnak, Carl H June, Bruce L Levine
The immune system evolved to distinguish non-self from self to protect the organism. As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge. This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumour microenvironment. The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed. Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy...
August 23, 2016: Nature Reviews. Cancer
J Y Zhang, Q Wang, S S Lin, J W Chen, H L Zhong, D Q Ca, Z G Chen
OBJECTIVE: To investigate the incidence and features of myopia in children aged 7 to 14 years. METHODS: Cross-sectional study. A total of 2 226 children (2 226 eyes) aged 7 to 14 years were selected from school during June 2012 and January 2015. Refraction was measured by fast cycloplegic retinoscopy. SPSS16.0 was used to analyze the data. Ocular refractive parameters, including axial length (AL), corneal power, anterior chamber depth, and white to white, were measured by IOLMaster (version 5...
July 2016: [Zhonghua Yan Ke za Zhi] Chinese Journal of Ophthalmology
Christopher L Jenkins, Mark L Bagarazzi, Hans-Peter Kiem, Arnold J Levine, Dale Ando, Carl H June, Tony Reid, David W Emery
No abstract text is available yet for this article.
August 2016: Molecular Therapy: the Journal of the American Society of Gene Therapy
Karin Blomberg, Peter Griffiths, Yvonne Wengström, Carl May, Jackie Bridges
BACKGROUND: Compassion has been identified as an essential element of nursing and is increasingly under public scrutiny in the context of demands for high quality health care. While primary research on effectiveness of interventions to support compassionate nursing care has been reported, no rigorous critical overview exists. OBJECTIVES: To systematically identify, describe and analyse research studies that evaluate interventions for compassionate nursing care; assess the descriptions of the interventions for compassionate care, including design and delivery of the intervention and theoretical framework; and to evaluate evidence for the effectiveness of interventions...
October 2016: International Journal of Nursing Studies
Arif Khan, Suresh Durgam, Xiongwen Tang, Adam Ruth, Maju Mathews, Carl P Gommoll
OBJECTIVE: To investigate vilazodone, currently approved for major depressive disorder in adults, for generalized anxiety disorder (GAD). METHOD: Three randomized, double-blind, placebo-controlled studies showing positive results for vilazodone (2,040 mg/d) in adult patients with GAD (DSM-IV-TR) were pooled for analyses; data were collected from June 2012 to March 2014. Post hoc outcomes in the pooled intent-to-treat population (n = 1,462) included mean change from baseline to week 8 in Hamilton Anxiety Rating Scale (HARS) total score, psychic and somatic anxiety subscale scores, and individual item scores; HARS response (≥ 50% total score improvement) and remission (total score ≤ 7) at week 8; and category shifts, defined as HARS item score ≥ 2 at baseline (moderate to very severe symptoms) and score of 0 at week 8 (no symptoms)...
2016: Primary Care Companion to CNS Disorders
Yunjie Lu, Keli L Hippen, Amanda L Lemire, Jian Gu, Weizhi Wang, Xuhao Ni, Parvathi Ranganathan, Bruce L Levine, James L Riley, Carl H June, Laurence A Turka, David H Munn, Ramiro Garzon, Ling Lu, Bruce R Blazar
CD4(+)CD25(+)FoxP3(+) thymic-derived regulatory T cells (tTregs) are indispensable for maintaining immune system equilibrium. Adoptive transfer of tTregs is an effective means of suppressing graft-versus-host disease (GVHD) in murine models and in early human clinical trials. Tumor necrosis factor receptor-associated factor 6 (TRAF6), an ubiquitin-conjugating enzyme that mediates nuclear factor κB (NF-κB) activation, plays an essential role in modulating regulatory T cell survival and function. MicroRNAs (miRNAs) are noncoding RNAs, which mediate RNA silencing and posttranscriptional gene repression...
September 8, 2016: Blood
Marco Ruella, Carl H June
Genetic redirection of T lymphocytes allows us to unleash these potent cellular immune effectors against cancer. Chimeric antigen receptor (CAR) T cells are the best-in-class example that genetic engineering of T cells can lead to deep and durable responses, as has been shown in several clinical trials for CD19+ B cell malignancies. As a consequence, in the last few years, several academic institutions and commercial partners have started developing anti-CD19 CAR T cell products. Although most of these T cell products are highly effective in vivo, basic differences among them can generate different performance characteristics and thereby impact their long-term clinical outcome...
October 2016: Current Hematologic Malignancy Reports
Emese Zsiros, Denarda Dangaj, Carl H June, Lana E Kandalaft, George Coukos
Tumor barriers preventing T-cell homing and engraftment should be neutralized during cancer immunotherapy. We recently discovered that ovarian cancer expresses quasi-universal chemokines that can support T-cell homing. Furthermore, T cells elicited by whole tumor antigen dendritic-cell vaccines express cognate chemokine receptors which are upregulated by CD3/CD28 costimulation.
May 2016: Oncoimmunology
John W Severinghaus
During the last century, historians have discovered that between the 13th and 18th centuries, at least six sages discovered that the air we breathe contains something that we need and use. Ibn al-Nafis (1213-1288) in Cairo and Michael Servetus (1511-1553) in France accurately described the pulmonary circulation and its effect on blood color. Michael Sendivogius (1566-1636) in Poland called a part of air "the food of life" and identified it as the gas made by heating saltpetre. John Mayow (1641-1679) in Oxford found that one-fifth of air was a special gas he called "spiritus nitro aereus...
September 2016: Advances in Physiology Education
Lei Wei, Jianmin Wang, Erika Lampert, Simon Schlanger, Adam D DePriest, Qiang Hu, Eduardo Cortes Gomez, Mitsuko Murakam, Sean T Glenn, Jeffrey Conroy, Carl Morrison, Gissou Azabdaftari, James L Mohler, Song Liu, Hannelore V Heemers
BACKGROUND: Next-generation sequencing is revealing genomic heterogeneity in localized prostate cancer (CaP). Incomplete sampling of CaP multiclonality has limited the implications for molecular subtyping, stratification, and systemic treatment. OBJECTIVE: To determine the impact of genomic and transcriptomic diversity within and among intraprostatic CaP foci on CaP molecular taxonomy, predictors of progression, and actionable therapeutic targets. DESIGN, SETTING, AND PARTICIPANTS: Four consecutive patients with clinically localized National Comprehensive Cancer Network intermediate- or high-risk CaP who did not receive neoadjuvant therapy underwent radical prostatectomy at Roswell Park Cancer Institute in June-July 2014...
July 20, 2016: European Urology
Anne Straily, Amanda Feldpausch, Carl Ulbrich, Kiersten Schell, Shannon Casillas, Sherif R Zaki, Amy M Denison, Marah Condit, Julie Gabel, Christopher D Paddock
During 2012-2014, five cases of Rickettsia parkeri rickettsiosis were identified by a single urgent care practice in Georgia, located approximately 40 miles southwest of Atlanta. Symptom onset occurred during June-October, and all patients had a known tick bite. Patients ranged in age from 27 to 72 years (median = 53 years), and all were male. The most commonly reported initial signs were erythema (n = 3) and swelling (n = 2) at the site of the bite. Two patients reported fever and a third patient reported a rash and lymphadenopathy without fever...
2016: MMWR. Morbidity and Mortality Weekly Report
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"